Printer Friendly

Kadmon Touts Data Demonstrating the Potential of Its New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions.

M2 PHARMA-June 1, 2017-Kadmon Touts Data Demonstrating the Potential of Its New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions


- US-based biopharmaceutical company Kadmon Holdings, Inc. (NYSE: KDMN) has released preclinical data demonstrating the potential of the company's new glucose transporter inhibitors to treat autoimmune and inflammatory conditions, the company said.

These are the first findings to be presented from Kadmon's GLUT inhibitor program, which will be shared as a poster at the Keystone Symposia on Integrating Metabolism and Immunity this week in Dublin, Ireland.

Kadmon researchers have developed potent, oral inhibitors of glucose transport, with the aim of blocking aberrant immune cell activity.

The company said its GLUT inhibitors have a good pharmacokinetic profile and directly block glucose uptake.

Experiments in isolated human T cells demonstrated that these GLUT inhibitors blocked the secretion of pro-inflammatory cytokines, such as IL-17 and TNF-alpha, and modulated key intracellular signaling pathways in pathogenic T cells, including STAT1, STAT3 and S6K.

Importantly, these GLUT inhibitors were well tolerated and reduced inflammation in mouse models at therapeutically relevant doses.

These findings provide the foundation to advance Kadmon's GLUT inhibitors toward clinical development.

Kadmon Holdings is a biopharmaceutical company focused on developing innovative products for significant unmet medical needs. The company has a product pipeline in autoimmune and fibrotic diseases, oncology and genetic diseases.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 1, 2017
Previous Article:Bone Morphogenetic Protein Market to Grow With a CAGR 3.1% by 2023, Research and Markets Forecasts.
Next Article:Innovus Pharma Touts Positive Pre-Clinical Synergistic Effects of Vesele in Combination with Sildenafil (Viagra) on Nitric Oxide Production.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters